The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

Mounjaro is a prescription glucagon-like peptide-1 (GLP-1) drug with the active ingredient tirzepatide. Doctors prescribe it for the treatment of type 2 diabetes, but they may also prescribe it ...

See which services passed our rigorous vetting process. Share on Pinterest Mounjaro (tirzepatide) is an injectable medication that’s approved for diabetes by the Food and Drug Administration (FDA).

Mounjaro (tirzepatide) has potential interactions with other medications and some supplements. For example, Mounjaro can interact with Adderall and oral birth control. An interaction can occur ...